Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells
Epigenetic modifications could drive some of the molecular events implicated in proliferation, drug resistance and metastasis of pancreatic ductal adenocarcinoma (PDAC). Thus, epigenetic enzyme inhibitors could be the key to revert those events and transform PDAC into a drug-sensitive tumor. We perf...
Saved in:
Main Authors: | Immacolata Maietta (Author), Amparo Martínez-Pérez (Author), Rosana Álvarez (Author), Ángel R. De Lera (Author), África González-Fernández (Author), Rosana Simón-Vázquez (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gemcitabine-Vitamin E Prodrug-Loaded Micelles for Pancreatic Cancer Therapy
by: Miguel Pereira-Silva, et al.
Published: (2024) -
Gemcitabine Combination Nano Therapies for Pancreatic Cancer
by: Kamalika Samanta, et al.
Published: (2019) -
Synergistic HIV latency reversal from an in vitro screen of epigenetic and kinase inhibitors
by: D. Irlbeck, et al.
Published: (2017) -
Epigenetic therapy: BBC1115, a novel BET inhibitor with broad antitumor activity
by: Pradeep Reddy Cingaram
Published: (2023) -
Synergistic effects of autophagy/mitophagy inhibitors and magnolol promote apoptosis and antitumor efficacy
by: Yancheng Tang, et al.
Published: (2021)